- Company
- Hunterase by GC Pharma is entering the Chinese market
- by Chon, Seung-Hyun Sep 11, 2020 06:28am
- Hunterase by Green Cross is entering the Chinese market GC Pharma announced on the 9th that Hunterase, a treatment for Hunter syndrome, has obtained a license from the NMPA of China. This is the first time that a drug for Hunter syndrome has been approved in China. GC Pharma applied for Hunterase's item license, July of last year in Chi
- Company
- Hanmi to turn efpeglenatide crisis around with new partner
- by An, Kyung-Jin Sep 10, 2020 06:24am
- Hanmi Pharmaceutical’s glucagon-like peptide-1 (GLP-1) agonist ‘efpeglenatide,’ initially licensed out to a global pharmaceutical company Sanofi in 2015, was ultimately returned to the South Korean company. Four months after when the global company indicated its intention to return the rights on the drug May, Sanofi has decided to suspend
- Company
- Pfizer pays ￦12 million to Upjohn‘s employees
- by Sep 10, 2020 06:23am
- Pfizer Pharmaceuticals Korea decided to pay ￦12 million in consolation to the employees of Upjohn who were transferred to Viatris, which was created as a merger with Mylan. According to the pharmaceutical industry on the 8th, Pfizer Pharmaceutical Korea has concluded negotiations with the union on consolation payments following the divis
- Company
- KDDF invests KRW 263 bln for 9 years but goal unachieved
- by Chon, Seung-Hyun Sep 9, 2020 05:52am
- The three government ministries’ first project to provide all-around support on new drug development, the Korea Drug Development Fund (KDDF) has ended its nine-year program. Although the goal of ‘developing 10 global new drugs’ was unachieved and the initially planned budget fell short, the project resulted in 50 license-out deals and it
- Company
- Botulinum share in domestic market is 93%
- by Chon, Seung-Hyun Sep 9, 2020 05:47am
- Among domestically produced and imported botulinum toxin preparations, products developed by Korean companies accounted for more than 90%. Following Medytox, Hugel, and Daewoong Pharmaceutical, Huons Global and Pharma Research joined. The three types of Meditoxin, whose license was decided to be canceled, recorded ￦82.2 billion in production la
- Company
- Jung-Jin Seo, COVID-19 tx will be applied within this year
- by An, Kyung-Jin Sep 9, 2020 05:46am
- Jung-Jin Seo, Chairman at Celltrion announced that he will apply for approval for emergency use of COVID-19 antibody treatment within this year. The strategy is to finish early phase I clinical trial of the COVID-19 antibody treatment, which started at the end of July, and start an integrated phase II and III clinical trial at the end o
- Company
- The government is worried about the generic exclusivity
- by Kim, Jin-Gu Sep 8, 2020 06:12am
- The generic exclusivity system is about to change in the fifth year of its introduction. Until now, the industry has been criticized for 'free ride' over this system. The core of the system is the grant of monopoly rights, and the contradictory situation in which monopoly was impossible was repeated. The discrimination power was lowered
- Company
- The dismissal of an executive in Lundbeck Korea was unfair
- by An, Kyung-Jin Sep 8, 2020 06:11am
- The National Labor Relations Commission issued an order to reinstate the job, saying that the dismissal of former executives in Lundbeck Korea was unfair. According to related industries on the 7th, the National Labor Relations Commission held an interrogation meeting on July 30 and sided with Mr. A in the case of a ``unfair dismissal req
- Company
- The contradiction of generic exclusivity
- by Kim, Jin-Gu Sep 7, 2020 06:13am
- Let's imagine! This is the case when the rule for '1st place' in a marathon is set to be '14 seconds after the first goal scored'. Competition will become meaningless, and only fights will increase. The achievements of legitimate efforts that the first place should receive will be shared by numerous 'joint first prizes'. The controversy
- Company
- Court to rule against companies on eye drop pricing?
- by Chon, Seung-Hyun Sep 7, 2020 06:12am
- The end in two years of legal dispute over the eye drop pricing reduction seems to be approaching. The Supreme Court has ultimately ruled against pharmaceutical companies on one of the two pricing reduction litigation cases. And as the government has won both the first and second trials over the other case, it would be unlikely for the pharmaceu
